

Hallgeir Rui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6596173/publications.pdf>

Version: 2024-02-01

63
papers

2,511
citations

218592

26
h-index

206029

48
g-index

67
all docs

67
docs citations

67
times ranked

3616
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. <i>Genesis</i> , 2004, 40, 52-57.	0.8	244
2	Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 2053-2060.	0.8	217
3	Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. <i>Cancer Cell</i> , 2017, 31, 194-207.	7.7	179
4	Differential Control of the Phosphorylation State of Proline-juxtaposed Serine Residues Ser725 of Stat5a and Ser730 of Stat5b in Prolactin-sensitive Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 30218-30224.	1.6	132
5	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. <i>Cancer Cell</i> , 2019, 35, 33-45.e6.	7.7	125
6	Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 2448-2458.	0.8	97
7	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. <i>Cancer Research</i> , 2018, 78, 1657-1671.	0.4	97
8	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9298-E9307.	3.3	91
9	Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. <i>Cell Reports</i> , 2016, 15, 171-180.	2.9	83
10	Role of serine phosphorylation of Stat5a in prolactin-stimulated β -casein gene expression. <i>Molecular and Cellular Endocrinology</i> , 2001, 183, 151-163.	1.6	80
11	Prolactin Inhibits BCL6 Expression in Breast Cancer through a Stat5a-Dependent Mechanism. <i>Cancer Research</i> , 2010, 70, 1711-1721.	0.4	68
12	Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 1821-1830.	0.4	66
13	Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. <i>Breast Cancer Research</i> , 2012, 14, R130.	2.2	63
14	Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways. <i>Molecular Endocrinology</i> , 2007, 21, 2218-2232.	3.7	58
15	Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. <i>American Journal of Pathology</i> , 2015, 185, 2505-2522.	1.9	54
16	Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R11.	2.2	53
17	Triggering ubiquitination of <i>IFNAR1</i> protects tissues from inflammatory injury. <i>EMBO Molecular Medicine</i> , 2014, 6, 384-397.	3.3	52
18	The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2328-2337.	1.1	49

#	ARTICLE	IF	CITATIONS
19	Blocking the Adhesion Cascade at the Premetastatic Niche for Prevention of Breast Cancer Metastasis. <i>Molecular Therapy</i> , 2015, 23, 1044-1054.	3.7	46
20	Ultra-high density microarrays of solid samples. <i>Nature Methods</i> , 2005, 2, 511-513.	9.0	42
21	Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1777-1793.	1.9	42
22	Insensitivity of Human Prolactin Receptors to Nonhuman Prolactins: Relevance for Experimental Modeling of Prolactin Receptor-Expressing Human Cells. <i>Endocrinology</i> , 2009, 150, 1782-1790.	1.4	40
23	The effect of soluble E-selectin on tumor progression and metastasis. <i>BMC Cancer</i> , 2016, 16, 331.	1.1	39
24	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. <i>Cell Reports</i> , 2021, 37, 109934.	2.9	34
25	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. <i>Oncotarget</i> , 2017, 8, 81754-81775.	0.8	32
26	Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H1267-H1280.	1.5	30
27	The p52 isoform of SHC1 is a key driver of breast cancer initiation. <i>Breast Cancer Research</i> , 2019, 21, 74.	2.2	29
28	Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. <i>Cancer Research</i> , 2021, 81, 5336-5352.	0.4	27
29	Global profiling of prolactin-modulated transcripts in breast cancer in vivo. <i>Molecular Cancer</i> , 2013, 12, 59.	7.9	26
30	E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e399.	2.3	26
31	Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1990-2002.	0.3	25
32	Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. <i>Modern Pathology</i> , 2016, 29, 1143-1154.	2.9	25
33	Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. <i>Nature Communications</i> , 2021, 12, 3742.	5.8	24
34	Exploring drivers of gene expression in the Cancer Genome Atlas. <i>Bioinformatics</i> , 2019, 35, 62-68.	1.8	21
35	Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78, a co-receptor for SARS-CoV-2, in COVID-19 autopsies. <i>Cell Stress and Chaperones</i> , 2021, 26, 859-868.	1.2	20
36	Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 6355-6366.	3.2	16

#	ARTICLE	IF	CITATIONS
37	The membrane-associated form of cyclin D1 enhances cellular invasion. <i>Oncogenesis</i> , 2020, 9, 83.	2.1	16
38	Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. <i>Oncogene</i> , 2020, 39, 6129-6137.	2.6	16
39	Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. <i>Toxicology and Applied Pharmacology</i> , 2015, 287, 86-92.	1.3	13
40	Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
41	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. <i>Science Advances</i> , 2021, 7, eabc8145.	4.7	10
42	Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population. <i>Military Medicine</i> , 2017, 182, e1851-e1858.	0.4	8
43	Quantification of spatial tumor heterogeneity in immunohistochemistry staining images. <i>Bioinformatics</i> , 2021, 37, 1452-1460.	1.8	8
44	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
45	Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer. <i>Cancers</i> , 2022, 14, 308.	1.7	8
46	Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. <i>Cancer Biology and Therapy</i> , 2020, 21, 629-636.	1.5	7
47	Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 5895-5905.	0.7	7
48	Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer. <i>Cancers</i> , 2020, 12, 725.	1.7	6
49	Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on Injury. <i>Cancers</i> , 2020, 12, 983.	1.7	6
50	Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients. <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 1739-1743.	0.8	5
51	Theory, methods, and operational results of the Young Women's Health History Study: a study of young-onset breast cancer incidence in Black and White women. <i>Cancer Causes and Control</i> , 2021, 32, 1129-1148.	0.8	4
52	Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. <i>Pathology</i> , 2022, 54, 404-408.	0.3	4
53	Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 77-91.	1.1	3
54	Individualized multi-omic pathway deviation scores using multiple factor analysis. <i>Biostatistics</i> , 2020, , .	0.9	3

#	ARTICLE	IF	CITATIONS
55	Mapping Mammary Tumor Traits in the Rat. <i>Methods in Molecular Biology</i> , 2019, 2018, 249-267.	0.4	3
56	Diffuse interstitial pneumonia-like/macrophage activation syndrome-like changes in patients with COVID-19 correlate with length of illness. <i>Annals of Diagnostic Pathology</i> , 2021, 53, 151744.	0.6	2
57	Adverse Effects of Chemotherapy on Human Microvascular Function. <i>FASEB Journal</i> , 2019, 33, lb453.	0.2	2
58	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022, 82, P5-17-08-P5-17-08.	0.4	2
59	ASO Author Reflections: Does Prompt Breast-Conserving Surgery Matter?. <i>Annals of Surgical Oncology</i> , 2021, 28, 5906-5906.	0.7	0
60	New Insights into the Role of SmgGDS as a Major Integrator of Signaling by Ras and Rho Family Members in Cancer. <i>FASEB Journal</i> , 2018, 32, 661.8.	0.2	0
61	Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. <i>Cancer Research</i> , 2022, 82, OT2-16-01-OT2-16-01.	0.4	0
62	Abstract P4-02-03: HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P4-02-03-P4-02-03.	0.4	0
63	A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS220-TPS220.	0.8	0